Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Alcohol septal ablation (ASA) is an established percutaneous intervention for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) refractory to medical therapy. Since its introduction in the mid-1990s, it has evolved through refinements in myocardial contrast echocardiography and target vessel selection. The following sections highlight the foundational, registry-based, and state-of-the-art literature.

---

Foundational Research

The conceptual origin of inducing a localized septal infarction to relieve left ventricular outflow tract (LVOT) obstruction was first published by Ulrich Sigwart in 1995.

• Sigwart, U. (1995). Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. The Lancet, 346(8969), 211–214.
  • Significance: This landmark paper described the first three successful cases of percutaneous alcohol injection into the first septal perforator, demonstrating an immediate reduction in the LVOT gradient and providing a minimally invasive alternative to surgical myectomy.

---

Key Registries and Meta-Analyses

Long-term safety and efficacy data are primarily derived from large multinational registries and systematic reviews comparing ASA to the surgical “gold standard.”

• Veselka et al. (2016). Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. European Heart Journal, 37(19), 1517–1523.
  • Significance: The largest multinational ASA registry (1,275 patients) reported a 30-day mortality of 1% and a 10-year survival rate of 77%. It established that residual LVOT gradient at follow-up is a strong predictor of long-term prognosis.
• Liebregts et al. (2015). A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC: Heart Failure, 3(11), 896–905.
  • Significance: This study found that while long-term mortality and sudden cardiac death (SCD) rates were similar between ASA and surgical myectomy, ASA was associated with a significantly higher risk of permanent pacemaker implantation (10% vs. 4.4%) and a five-fold higher rate of reintervention (7.7% vs. 1.6%).

---

Current State-of-the-Art & Guidelines

Modern management emphasizes shared decision-making and the role of multidisciplinary “Heart Teams” in comprehensive HCM centers.

Clinical Guidelines

• Ommen et al. (2024). 2024 AHA/ACC Guideline for the Management of Hypertrophic Cardiomyopathy. Circulation.
  • Significance: These guidelines recommend ASA as a Class 1 strategy for symptomatic patients with resting or provoked gradients ≥ 50 mmHg. While myectomy is often preferred in younger patients or those with complex mitral valve anatomy, ASA is highly recommended for older adults or those with significant comorbidities.

Recent Comparative Developments

• ASA vs. Myosin Inhibitors: Recent research has compared ASA with novel pharmacotherapies like mavacamten. Both therapies achieve comparable reductions in afterload and improvements in diastolic filling pressures, though mavacamten may show a more pronounced reduction in left atrial volume index over time.
• ASA vs. Radiofrequency Ablation (PESA): A comparative study noted that while ASA provides superior reduction in LVOT gradients and septal thickness, percutaneous endocardial septal radiofrequency ablation (PESA) is significantly more effective at avoiding bundle branch blocks and conduction disturbances.

---